KRAS-driven lung adenocarcinoma treated with KRAS inhibitors initially exhibit features of alveolar type 2 (AT2) cells but upon treatment withstand therapy by acquiring features of alveolar type 1 (AT1) cells (67). Here, KRAS is linked to lung adenocarcinoma.